Trial Profile
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Brain metastases; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 03 Apr 2020 Results published in the Lancet Oncology
- 27 Feb 2020 Status changed from active, no longer recruiting to completed.
- 08 Nov 2018 Results published in the Journal of Clinical Oncology